SGR-2921

Near Add Your Location

Accepting patients

SGR-2921

A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Learn more
  • CDC7 Inhibitor
  • Phase 1